CLSI Blog Articles

Read the latest articles about CLSI and laboratory standards in the official CLSI Blog. Browse our most recent blog articles below.

CLSI President Dr. James Nichols on the Importance of Preparing Students for Laboratory Medicine Careers

We are excited to celebrate CLSI Board President Dr. James Nichols, who has been awarded the 2024 Association for Diagnostics & Laboratory Medicine “Outstanding Contributions to Education in Clinical Chemistry.” This award is bestowed upon an individual who has dedicated a significant portion of their professional career to advancing the practice and profession of clinical chemistry through education. Dr. Nichols has been selected for this award in recognition of his remarkable and innovative contributions to education in clinical laboratory science as a faculty member and an active community leader on boards, committees, and councils over 30 years.

Learn, Grow, and Connect with CLSI at ADLM 2024!

CLSI will be participating in the Association for Diagnostics & Laboratory Medicine (ADLM) 2024 Annual Meeting and Expo in Chicago, IL from 28 July through 31 August. We’ll be at booth 3468 in the expo center to answer questions, provide support for users and members, and showcase new standards and products, including CLSI’s new Method Navigator tool.

CLSI AST Standards: New Guidelines Help Slow Spread of Antimicrobial Resistance

CLSI recently published the 34th edition of CLSI M100—Performance Standards for Antimicrobial Susceptibility Testing, as well as new editions of standards documents, CLSI M02 and CLSI M07.1, 2, 3 Using guidance like CLSI M100, M02, and M07 can help slow the spread of antimicrobial resistance (AMR), one of the leading global public health and development threats.

World Health Day: Celebrating 75 Years of Health Advocacy

On April 7th, we commemorate World Health Day, which marks the 75th anniversary of the establishment of the World Health Organization (WHO), in 1948. This year’s theme, “My Health, My Right,” emphasizes the fundamental right of every individual to access quality health services, education, and information. It also underscores the importance of safe drinking water, clean air, good nutrition, quality housing, decent working and environmental conditions, and freedom from discrimination.

A Week for Collaboration and Consensus: CLSI’s January 2024 Meetings

CLSI’s Committees Weeks are an opportunity for the CLSI expert community to meet and connect with colleagues for a week of information sharing, consensus building, networking, and camaraderie. Committees Weeks are where the hard work behind CLSI’s standards and guidelines takes place—committees and subcommittees, following CLSI’s voluntary consensus process, work together on new and revised CLSI standards in development.

AST News Update January 2024: Acinetobacter – the Bad, the Awful, and the Downright Ugly

Between 2018-2021, the National Healthcare Safety Network (NHSN) reported that 0.4% (n=1,951) of hospital-acquired infections (HAIs) in the United States were caused by Acinetobacter spp. Of these, 28-45% were not susceptible to carbapenem antibiotics (ie, intermediate or resistant).1 CDC’s 2019 Antibiotic Resistance Threats Report estimated that there were 8,500 carbapenem-resistant Acinetobacter cases in hospitalized patients in 2017.2 Consistently, the A. calcoaceticus-A. baumannii complex (A. baumannii) is the largest cause of clinical Acinetobacter spp. infections and is most often recovered from respiratory specimens.

AST News Update January 2024: Antifungal Body Site Reporting for Candida spp.

A 59-year-old woman with metastatic breast cancer was admitted to a hospital for fever and suspected sepsis 12 days after chemotherapy-induced neutropenia (<1,000 neutrophils/μL in peripheral blood; normal range 2500-7000 neutrophils/μL). The patient was started empirically on cefepime, vancomycin, and anidulafungin. Two sets of blood cultures grew Candida tropicalis on day 3 post admission. Since this isolate was recovered from the blood, both species-level identification and susceptibility testing were performed. At the time of blood culture positivity, the patient did not report any visual symptoms, and dilated fundoscopy of the eyes on day 4 did not reveal any signs of ocular involvement.

AST News Update January 2024: Practical Tips for Using Newly Formatted Tables 1 in CLSI M100 33rd Edition

In 1972, CLSI, formerly known as the National Committee for Clinical Laboratory Standards (NCCLS), published “Table 1” in one of the earliest NCCLS AST documents. Table 1 was intended to help clinical laboratories decide which antimicrobial agents to test and report on specific bacteria. New drugs and new comments were added to the Tables 1 over the ensuing decades, but the format for these tables did not change.

AST News Update January 2024: Sulbactam-Durlobactam: The “double beta-lactamase inhibitor” drug

Many laboratorians are familiar with sulbactam, a β-lactamase inhibitor that is commercially combined with ampicillin, which was introduced in the US in 1986 to make ampicillin-sulbactam (“Unasyn”). Like many older β-lactamase inhibitors, sulbactam is itself a β-lactam, but has poor antimicrobial activity against most bacteria.

New Training Course for Latin American and Caribbean Veterinary Labs Results in Stronger Standards, Safer Food

CLSI recently partnered with the Ohio State University (Ohio State) and the Inter-American Institute for Cooperation on Agriculture (IICA) for the first training of its kind that brought together official veterinary diagnosticians in Latin America and the Caribbean (LAC) working in national reference labs monitoring antimicrobial resistance (AMR).